Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
Sorrento will provide new data on recent advances in allogeneic cellular therapy research, including but not limited to 3 clinical areas Sorrento has been focusing on:
- original Dimeric Antigen Receptor DAR (proprietary) approach
- non-viral gene editing knock-out knock-in KOKI (proprietary) technology
- allogeneic manufacturing aiming at increasing capacity and reducing end-patient-costs
Examples from the CD38 and BCMA programs will illustrate current progress in key development areas.
Several scientific posters will be presented at the upcoming
Zhangjiang International Summit on Cell Therapy 2019
Next-generation off-the-shelf CAR-T cell therapy
Keynote Speaker, Dr.
- Development of an Allogeneic Anti-BCMA T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure. Poster and audio.
- Development of a Genetically Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure. Poster and audio.
- Preclinical characterization of an anti-CD38/CD3 T Cell- redirecting bispecific antibody. Poster and audio.
- Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies. (Sorrento sourced technology presented by Celularity).
- Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) as Allogeneic Cancer Immunotherapy. (Sorrento sourced technology presented by Celularity).
- Ex-vivo activity of immuno-therapeutic approaches targeting CD38 against Daratumumab-resistant multiple myeloma patient samples. (Collaborative work between Sorrento and Karolinska institute). Late breaking abstract submission.
ASH online (following scientific conference)
- Preclinical Development of a BCMA Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy. Selected for inclusion in November supplemental issue of Blood and for ASH online abstracts.
- Preclinical Development of a CD38 Targeting Antibody-Drug Conjugate for Treatment of Hematological Malignancies. Selected for inclusion in November supplemental issue of Blood and for ASH online abstracts.
Longwood Annual Winter Meeting at
Identifying Novel Technologies and Therapeutic Areas
Expert panel discussion with Dr.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its’ extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), antibody-drug conjugates (“ADC”) as well CAR-T and oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) RTX and ZTlido®. RTX is completing a phase IB trial in terminal cancer patients. ZTlido® was approved by US FDA on
For more information visit www.sorrentotherapeutics.com
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations
ZTlido® and G-MAB™ are trademarks owned by
Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of
All other trademarks are the property of their respective owners.
Source: Sorrento Therapeutics, Inc.